Nadia Marascio, Angela Quirino, Giorgio Settimo Barreca, Luisa Galati, Chiara Costa, Vincenzo Pisani, Maria Mazzitelli, Giovanni Matera, Maria Carla Liberto, Alfredo Focà, Carlo Torti
Clin Mol Hepatol 2019;25(1):30-36. Published online January 23, 2019
Hepatitis C virus (HCV) infects around 71 million people worldwide and in 2018 it is still a major health problem. Since 2011, anti-HCV therapy with availability of direct-acting antiviral drugs has revolutionized the clinical response and paved the way to eradication strategies. However, despite the high rate of sustained virological response, treatment failure may occur in a limited percentage of patients, possibly due to resistance-associated substitutions (RASs), either emergent or pre-existent even in minority viral populations. Clearly this problem may impair success of eradication strategies. With this background, several questions marks still exist around HCV treatment, including whether pan-genotypic treatments with complete effectiveness in any clinical conditions really exist outside clinical trials, the actual cost-effectiveness of genotyping testing, and utility of RAS detection in viral quasispecies by next generation sequencing approach. In this review, we describe these critical points by discussing recent literature data and our research experience.
Citations
Citations to this article as recorded by
Evaluating short-term and long-term liver fibrosis improvement in hepatitis C patients after DAA treatment Yifan Wang, Xinyan Ma, Yanzheng Zou, Ming Yue, Meiling Zhang, Rongbin Yu, Hongbo Chen, Peng Huang The Journal of Biomedical Research.2024; 38(5): 464. CrossRef
Laboratory Biochemical and Hematological Parameters: Early Predictive Biomarkers for Diagnosing Hepatitis C Virus Infection Saeede Bagheri, Ghazaleh Behrouzian Fard, Nasrin Talkhi, Davoud Rashidi Zadeh, Naser Mobarra, Seyedmahdi Mousavinezhad, Fatemeh Mirzaeian Khamse, Mahdi Hosseini Bafghi Journal of Clinical Laboratory Analysis.2024;[Epub] CrossRef
Differences in HCV Seroprevalence, Clinical Features, and Treatment Outcomes between Female and Male Incarcerated Population: Results from a Matched Cohort Study Vito Fiore, Andrea De Vito, Elena Rastrelli, Valentina Manca, Giuseppe De Matteis, Roberto Ranieri, Emanuele Pontali, Nicholas Geremia, Sandro Panese, Giulio Starnini, Giordano Madeddu, Sergio Babudieri Viruses.2023; 15(12): 2414. CrossRef
Similarities, differences, and possible interactions between hepatitis E and hepatitis C viruses: Relevance for research and clinical practice Nadia Marascio, Salvatore Rotundo, Angela Quirino, Giovanni Matera, Maria Carla Liberto, Chiara Costa, Alessandro Russo, Enrico Maria Trecarichi, Carlo Torti World Journal of Gastroenterology.2022; 28(12): 1226. CrossRef
HCV inhibits M2a, M2b and M2c macrophage polarization via HCV core protein engagement with Toll‑like receptor 2 Shixing Zhao, Meng Si, Xianpei Deng, Dengqin Wang, Lingbin Kong, Qianqian Zhang Experimental and Therapeutic Medicine.2022;[Epub] CrossRef
Circulating Genotypes of Hepatitis C Virus in Italian Patients before and after the Application of Wider Access Criteria to HCV Treatment Daniela Zago, Irene Pozzetto, Monia Pacenti, Giuseppina Brancaccio, Silvia Ragolia, Monica Basso, Saverio Giuseppe Parisi The Open Microbiology Journal.2022;[Epub] CrossRef
The Role of the Microbiota Gut–Liver Axis during HCV Chronic Infection: A Schematic Overview Nadia Marascio, Carmen De Caro, Angela Quirino, Maria Mazzitelli, Emilio Russo, Carlo Torti, Giovanni Matera Journal of Clinical Medicine.2022; 11(19): 5936. CrossRef
Epidemiology and Genotype Distribution of Hepatitis C Virus in Russia Nikolay Pimenov, Dmitry Kostyushev, Svetlana Komarova, Anastasia Fomicheva, Alexander Urtikov, Olga Belaia, Karina Umbetova, Olga Darvina, Natalia Tsapkova, Vladimir Chulanov Pathogens.2022; 11(12): 1482. CrossRef
Immunological Mechanisms for Hepatocellular Carcinoma Risk after Direct-Acting Antiviral Treatment of Hepatitis C Virus Infection Pil Soo Sung, Eui-Cheol Shin Journal of Clinical Medicine.2021; 10(2): 221. CrossRef
Effect of directly acting antivirals for hepatitis C virus infection on proprotein convertase subtilisin/kexin type 9 level Carlo Torti, Vincenzo Scaglione, Bruno Mario Cesana, Chiara Costa, Nadia Marascio, Elisabetta Schiaroli, Chiara Busti, Sabrina Bastianelli, Maria Mazzitelli, Enrico Maria Trecarichi, Daniela Francisci Health Science Reports.2021;[Epub] CrossRef
Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report Fabián Aldunate, Natalia Echeverría, Daniela Chiodi, Pablo López, Adriana Sánchez-Cicerón, Martín Soñora, Juan Cristina, Gonzalo Moratorio, Nelia Hernández, Pilar Moreno BMC Infectious Diseases.2021;[Epub] CrossRef
Phylogenetic and Molecular Analyses of More Prevalent HCV1b Subtype in the Calabria Region, Southern Italy Nadia Marascio, Angela Costantino, Stefania Taffon, Alessandra Lo Presti, Michele Equestre, Roberto Bruni, Giulio Pisani, Giorgio Settimo Barreca, Angela Quirino, Enrico Maria Trecarichi, Chiara Costa, Maria Mazzitelli, Francesca Serapide, Giovanni Matera Journal of Clinical Medicine.2021; 10(8): 1655. CrossRef
Interferon Response in Hepatitis C Virus-Infected Hepatocytes: Issues to Consider in the Era of Direct-Acting Antivirals Pil Soo Sung, Eui-Cheol Shin International Journal of Molecular Sciences.2020; 21(7): 2583. CrossRef
HCV Antibody Prevalence and Genotype Evolution in a Teaching Hospital, Calabria Region, Southern Italy Over A Decade (2008-2018) Nadia Marascio, Maria Mazzitelli, Giuseppe G.M. Scarlata, Aida Giancotti, Giorgio S. Barreca, Angelo G. Lamberti, Francesca Divenuto, Chiara Costa, Enrico M. Trecarichi, Giovanni Matera, Maria C. Liberto, Carlo Torti The Open Microbiology Journal.2020; 14(1): 84. CrossRef
microRNA-99a Restricts Replication of Hepatitis C Virus by Targeting mTOR and De Novo Lipogenesis Eun Byul Lee, Pil Soo Sung, Jung-Hee Kim, Dong Jun Park, Wonhee Hur, Seung Kew Yoon Viruses.2020; 12(7): 696. CrossRef
Dissimilar Conservation Pattern in Hepatitis C Virus Mutant Spectra, Consensus Sequences, and Data Banks Carlos García-Crespo, María Eugenia Soria, Isabel Gallego, Ana Isabel de Ávila, Brenda Martínez-González, Lucía Vázquez-Sirvent, Jordi Gómez, Carlos Briones, Josep Gregori, Josep Quer, Celia Perales, Esteban Domingo Journal of Clinical Medicine.2020; 9(11): 3450. CrossRef
Hepatocellular Carcinoma Risk According to Regimens for Eradication of Hepatitis C Virus; Interferon or Direct Acting Antivirals Hye Won Lee, Dai Hoon Han, Hye Jung Shin, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim Cancers.2020; 12(11): 3414. CrossRef
The remaining challenges of HCV treatment in the direct‐acting antivirals era Beom Kyung Kim, Sang Hoon Ahn Journal of Gastroenterology and Hepatology.2019; 34(11): 1891. CrossRef
Alessio Strazzulla, Giuseppe Coppolino, Giorgio Settimo Barreca, Innocenza Gentile, Laura Rivoli, Maria Concetta Postorino, Maria Mazzitelli, Giuseppe Greco, Chiara Costa, Vincenzo Pisani, Nadia Marascio, Mariadelina Simeoni, Alfredo Focà, Giorgio Fuiano, Daniela Foti, Elio Gulletta, Carlo Torti
Clin Mol Hepatol 2018;24(2):151-162. Published online April 24, 2018
Background/Aims Correct renal function evaluation is based on estimated glomerular filtration rates (eGFR) and complementary renal damage biomarkers, such as neutrophil gelatinase associated lipocalin (NGAL). The aim of this study was to evaluate eGFR and NGAL modifications and renal impairment during treatment with a direct acting antiviral (DAA) for chronic hepatitis C virus (HCV) infection.
Methods A retrospective cohort study evaluated eGFR modification during treatment with DAA. Subgroup analysis on serum NGAL was conducted in those receiving sofosbuvir/ledipasvir, with complete follow-up until week 12 after the end of treatment (FU-12).
Results In the 102 enrolled patients, eGFR reduction was observed (from 86.22 mL/min at baseline to 84.43 mL/min at FU-12, P=0.049). Mean NGAL increased in 18 patients (from 121.89 ng/mL at baseline to 204.13 ng/mL at FU-12, P=0.014). At FU-12, 38.8% (7/18) of patients had a plasmatic NGAL value higher than the normal range (36-203 ng/mL) compared with 11.1% (2/18) at baseline (χ 2 =3,704; P=0.054). In contrast, eGFR did not change significantly over the follow-up in this subgroup.
Conclusions In conclusion, compared to a negligible eGFR decline observed in the entire cohort analyzed, a significant NGAL increase was observed after HCV treatment with DAA in a small subgroup. This could reflect tubular damage during DAA treatment rather than glomerular injury.
Citations
Citations to this article as recorded by
Dynamic changes and clinical value of lipocalin 2 in liver diseases caused by microbial infections Feng Chen, Shan-Shan Wu, Chao Chen, Cheng Zhou World Journal of Hepatology.2024; 16(2): 177. CrossRef
Evaluating short-term and long-term liver fibrosis improvement in hepatitis C patients after DAA treatment Yifan Wang, Xinyan Ma, Yanzheng Zou, Ming Yue, Meiling Zhang, Rongbin Yu, Hongbo Chen, Peng Huang The Journal of Biomedical Research.2024; 38(5): 464. CrossRef
Stem Cells in Kidney Ischemia: From Inflammation and Fibrosis to Renal Tissue Regeneration Rosario Cianci, Mariadelina Simeoni, Eleonora Cianci, Oriana De Marco, Antonio Pisani, Claudio Ferri, Antonietta Gigante International Journal of Molecular Sciences.2023; 24(5): 4631. CrossRef
Renal Stem Cells, Renal Resistive Index, and Neutrophil Gelatinase Associated
Lipocalin Changes After Revascularization in Patients With Renovascular Hypertension
and Ischemic Nephropathy Rosario Cianci, Mariadelina Simeoni, Antonietta Gigante, Adolfo Marco Perrotta, Sonia Ronchey, Nicola Mangialardi, Annalisa Schioppa, Oriana De Marco, Eleonora Cianci, Cristiana Barbati, Silvia Lai, Claudio Ferri Current Pharmaceutical Design.2023; 29(2): 133. CrossRef
Impact of Thyroid Cancer Treatment on Renal Function: A Relevant Issue to Be Addressed Rossella Di Paola, Ananya De, Anna Capasso, Sofia Giuliana, Roberta Ranieri, Carolina Ruosi, Antonella Sciarra, Caterina Vitagliano, Alessandra F. Perna, Giovambattista Capasso, Mariadelina Simeoni Journal of Personalized Medicine.2023; 13(5): 813. CrossRef
INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease Anil Arora, Ashish Kumar, Narayan Prasad, Ajay Duseja, Subrat K. Acharya, Sanjay K. Agarwal, Rakesh Aggarwal, Anil C. Anand, Anil K. Bhalla, Narendra S. Choudhary, Yogesh K. Chawla, Radha K. Dhiman, Vinod K. Dixit, Natarajan Gopalakrishnan, Ashwani Gupta, Journal of Clinical and Experimental Hepatology.2021; 11(3): 354. CrossRef
HCV cirrhotic patients treated with direct‐acting antivirals: Detection of tubular dysfunction and resolution after viral clearance Elisa Biliotti, Donatella Palazzo, Francesca Tinti, Maria Domenica D'Alessandro, Rozenn Esvan, Raffaella Labriola, Andrea Cappoli, Ilaria Umbro, Lorenzo Volpicelli, Alessandra Bachetoni, Erica Villa, Anna Paola Mitterhofer, Paola Rucci, Gloria Taliani Liver International.2021; 41(1): 158. CrossRef
Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals Yen-Chun Chen, Chen-Hao Li, Ping-Hung Ko, Chi-Che Lee, Ru-Jiang Syu, Chih-Wei Tseng, Kuo-Chih Tseng, Chen-Hua Liu PLOS ONE.2021; 16(8): e0256505. CrossRef
Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) in HCV-Positive Egyptian Patients Treated with Sofosbuvir Ali Nada, Mohamed Abbasy, Aliaa Sabry, Azza Mohamed Abdu Allah, Somaia Shehab-Eldeen, Nada Elnaidany, Hanan Elimam, Kawthar Ibraheem Mohamed Ibraheem, Abdallah Essa Canadian Journal of Gastroenterology and Hepatology.2020; 2020: 1. CrossRef
Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy) Vincenzo Scaglione, Maria Mazzitelli, Chiara Costa, Vincenzo Pisani, Giuseppe Greco, Francesca Serapide, Rosaria Lionello, Valentina La Gamba, Nadia Marascio, Enrico Maria Trecarichi, Carlo Torti Medicina.2020; 56(3): 101. CrossRef
Looking beyond Entecavir to discover Gitelman Syndrome in a 50 year-old man M Simeoni, V Columbano, Y Suzumoto, L Salviano, G Capolongo, M Zacchia, F Del Vecchio Blanco, A F Perna, V Nigro, G Capasso, F Trepiccione QJM: An International Journal of Medicine.2020; 113(10): 739. CrossRef
Hepatitis C virus and the kidney Stanislas Pol, Lucia Parlati, Michel Jadoul Nature Reviews Nephrology.2019; 15(2): 73. CrossRef
First
Prev
